Decitabine
- 1 November 2006
- journal article
- Published by Springer Nature in Nature Reviews Drug Discovery
- Vol. 5 (11), 891-892
- https://doi.org/10.1038/nrd2180
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Decitabine improves patient outcomes in myelodysplastic syndromesCancer, 2006
- DNA methylation and gene silencing in cancerNature Clinical Practice Oncology, 2005
- Methylation inhibitor therapy in the treatment of myelodysplastic syndromeNature Clinical Practice Oncology, 2005
- AzacitidineNature Reviews Drug Discovery, 2005
- Efficacy of Lenalidomide in Myelodysplastic SyndromesNew England Journal of Medicine, 2005
- Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2′-deoxycytidine (decitabine) treatmentBlood, 2002
- Low-Dose 5-Aza-2′-Deoxycytidine, a DNA Hypomethylating Agent, for the Treatment of High-Risk Myelodysplastic Syndrome: A Multicenter Phase II Study in Elderly PatientsJournal of Clinical Oncology, 2000
- MyelodysplasiaNew England Journal of Medicine, 1999
- Treatment of sickle cell anemia with 5-azacytidine results in increased fetal hemoglobin production and is associated with nonrandom hypomethylation of DNA around the gamma-delta-beta-globin gene complex.Proceedings of the National Academy of Sciences, 1983
- Cellular differentiation, cytidine analogs and DNA methylationCell, 1980